Philip P. Gutry's most recent trade in Graphite Bio Inc was a trade of 5,000 Common Stock done at an average price of $4.0 . Disclosure was reported to the exchange on April 11, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Purchase of securities on an exchange or from another person at price $ 4.01 per share. | 11 Apr 2022 | 5,000 | 299,941 | - | 4.0 | 20,050 | Common Stock |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 4,718 | 4,718 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 3,783 | 3,783 | - | - | Stock Option (Right to Buy) |